TB Alternative Assets Ltd. has joined the biotech investing party by purchasing 3,158 shares of Regeneron Pharmaceuticals ...

Regeneron founder, chairman and CEO Dr. Leonard Schleifer joins 'Squawk Box' to discuss the company's bid for 23andMe, ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has ...

Atwood & Palmer Inc. slightly reduced its stake in Regeneron Pharmaceuticals, selling 1,709 shares in Q1 while still holding ...

Shares of biotech company Regeneron (NASDAQ:REGN) fell 19% in the afternoon session after the company announced mixed results ...

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

US biotech Regeneron and French drugmaker Sanofi are reviewing next steps for their experimental COPD therapy itepekimab ...

For more comprehensive information about current price movements while Regeneron shares crash, please visit CDS.

Regneron stock crashed today following disappointing COPD trials data. Here's what makes REGN shares worth buying on the ...

The Shares of the biotech Kymera Therapeutics are up 50% since Monday, when data from an early trial hinted that its pill might relieve dermatitis and asthma comparably to the Regeneron ...

US biotech Regeneron Pharmaceuticals has announced detailed analyses from the Phase III C-POST trial, which evaluated PD-1 ...